Academic Founder: Professor Fergal O’Brien
SurgaColl™ Technologies is an innovative venture-funded medical device company supplying novel tissue regeneration products for the surgical treatment of disease of the bone, cartilage and other human tissue.
The company was spun-out of RCSI in 2012 with a foundational license to two ground-breaking RCSI technologies in the regenerative medicine space: HydroxyColl and ChondroColl. The company’s lead product, HydroxyColl, is a medical implant designed to replace the use of patient’s own bone tissue when repairing bone damaged by trauma or cancer. In November 2015, the company obtained CE Mark market approval for HydroxyColl and the first sale took place in 2017. Surgacoll is now seeking approval from the FDA to market HydroxyColl in the USA. The company’s second product, ChondroColl, repairs articular joints by stimulating host stem cells to regenerate both bone and cartilage, using the composition and architecture of the biomaterial to actively direct tissue formation. ChondroColl is highly effective in the treatment of early joint cartilage damage, particularly in the knee and is a significant advance for sports medicine. It is currently undergoing the European CE marking process. The Company continues to expand its manufacturing and R&D activities within Ireland and now employs eight FTE. The Innovation Office at RCSI supported company development from the outset, assisting with commercialisation funding applications, IP portfolio development and protection and prosecution and licensing. Both licensed patents are now granted many jurisdictions. The Innovation Team maintains an active dialog with the company and supports it through the establishment of new research collaborations, showcasing and licensing new technologies of interest.
Underpinning funding sources include: Enterprise Ireland, Science Foundation Ireland, Health Research Board, European Research Council
TTO Support: Company formation, Intellectual Property Strategy & Management, Funding Advice, Licensing